THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 199 PATIENT GROUPS with an interest in RARE DISEASES
|
|
- Allen Franklin
- 5 years ago
- Views:
Transcription
1 THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 199 PATIENT GROUPS with an interest in RARE DISEASES PUBLISHED MAY 2016
2 Dans notre domaine de maladies rares où des efforts ont été faits pour impliquer les patients. ( In our field of rare diseases, efforts have been made to involve patients. ) National France-based patient group specialising in rare neurological diseases in 2016, patientview is publishing 20 corporate reputation of pharma reports, analysing the results from the 1,075 patient groups responding to the 2015 survey. specialty reports: cancer I circulatory conditions I diabetes I hiv/aids I hepatitis I neurological conditions I mental health I respiratory conditions I skin conditions I rare diseases (10 reports) geographic-region reports: europe I eastern europe I germany I global I italy I latin america I nordic I spain I uk I usa (10 reports)
3 CONTENTS ABOUT THIS REPORT Page 1 WHAT DID RARE-DISEASE PATIENT GROUPS SAY ABOUT PHARMA IN 2015? Summary of the industry-wide findings (as judged by rare-disease patient groups) Page 3 A FEW COMMENTS ON THE RARE-DISEASE CORPORATE RANKINGS Page 6 WHAT CAN PHARMA COMPANIES DO TO IMPROVE THEIR CORPORATE REPUTATION? Page 7 COMMENTS FROM RARE-DISEASE PATIENT GROUPS, 2015 Page 8 METHODOLOGY OF THE PATIENT-GROUP SURVEY Page 12 APPENDIX 1: Data on how rare-disease patient groups see the pharmaceutical industry in 2015 Page 13 APPENDIX 2: Rankings of the 28 pharma companies for each of the 6 indicators of corporate reputation, as perceived by rare-disease patient groups in 2015 Page 18 APPENDIX 3: Profiles of the 28 companies Page 27 APPENDIX 4: Profiles of the 199 respondent rare-disease patient groups Page 57
4 LIST OF TABLES AND CHARTS BASED ON THE VIEWS OF RARE-DISEASE PATIENT GROUPS, 2015 Percentage of rare-disease patient groups claiming familiarity with the company Page 2 Percentage of rare-disease patient groups claiming familiarity with the company, and which also worked with it Page 2 Percentage of patient groups worldwide (by therapy area) stating that pharma is Excellent or Good at PROVIDING HIGH-QUALITY, USEFUL PRODUCTS Page 4 Percentage of patient groups worldwide (by therapy area) stating that pharma is Excellent or Good at PATIENT SAFETY Page 5 Top-ten pharma companies 2015, according to patient groups specialising in rare diseases (v. rare diseases ranking, 2014) Page 6 If a pharma company wishes to improve its corporate reputation with patients and patient groups, which single strategy from the list below do you think would be MOST IMPORTANT for the company to follow? Please select only ONE option Page 7 How do you think your organisation s members (or the people you represent) would rate the corporate reputation of the following healthcare sectors in 2015? Page 14 What do you think has happened to the corporate reputation of the pharma industry over the past five years? Page 15 How good or bad do you think the pharma industry is in 2015 at carrying out the following activities (all of which influence their corporate standing with patients and patient groups)? Page 16 How good or bad do you think the pharma industry is in 2015 at carrying out the following activities (all of which influence their corporate standing with patients and patient groups)? Page 17 Companies with the most effective PATIENT-CENTRED STRATEGY (rankings of 28 companies, 2015) Page 19 Companies providing the best HIGH-QUALITY PATIENT INFORMATION (rankings of 28 companies, 2015) Page 20 Companies with the best record on PATIENT SAFETY (rankings of 28 companies, 2015) Page 21 Companies with the most-useful HIGH-QUALITY PRODUCTS (rankings of 28 companies, 2015) Page 22 Companies with the best record of TRANSPARENCY (rankings of 28 companies, 2015) Page 23 Companies with the best record on INTEGRITY (rankings of 28 companies, 2015) Page 24 Rankings of the 28 pharmaceutical companies in 2015, alphabetic order Page 25 Rankings of the 28 pharmaceutical companies in 2015, highest to lowest Page 26 Geographic headquarters of 2015 s 199 respondent rare-disease patient groups by country Page 57 Geographic remit of 2015 s 199 respondent rare-disease patient groups Page 57
5 LIST OF TABLES AND CHARTS CONTINUED AbbVie page 29 Actavis page 30 Allergan page 31 Amgen page 32 AstraZeneca page 33 Baxalta page 34 Bayer page 35 Biogen Idec page 36 Boehringer Ingelheim page 37 B-MS page 38 Celgene page 39 Eli Lilly page 40 Gilead Sciences page 41 GSK page 42 Janssen page 43 Lundbeck page 44 Merck & Co (US) page 45 Merck KGaA page 46 Novartis page 47 Novo Nordisk page 48 Pfizer page 49 Roche page 50 Sandoz page 51 Sanofi page 52 Shire page 53 Takeda page 54 Teva page 55 UCB page 56 profiles of the 28 companies, according to the rare-disease patient groups familiar with these companies, or which have worked with them Each profile contains... company background information Annual revenue (latest-available year), comprising amount in currency, as quoted by the profiled company itself. = increase in revenue over the previous year or = decrease in revenue. The profiled company s main treatment subject areas (and areas of R&D). A mission statement from the profiled company. how the company has performed at six indicators of corporate reputation The profiled company s performance at the six indicators of corporate reputation in 2015, according to the rare-disease patient groups familiar with the company. The profiled company s performance at the six indicators of corporate reputation, according to the rare-disease patient groups that have worked with the company. How the profiled company performed among rare-disease patient groups for different countries/regions, compared with the company s global averages for rare-disease patient groups in how the company ranks for corporate reputation compared with other companies The profiled company s rankings among rare-disease patient groups in 2015 for the six indicators of corporate reputation, compared with 27 other companies. The profiled company s rankings worldwide in 2015 for the six indicators of corporate reputation, compared with 47 other companies. profile of the patient groups familiar with the company Other companies that partner with a significant number of the profiled company s partner patient groups. The countries of the patient groups familiar with the profiled company. Janssen Pharmaceutical Companies of Johnson & Johnson
6 Contact details PatientView Registered office: One Fleet Place, London, EC4M 7WS, UK Tel: +44-(0) Registered in England, number: Data protection registration number: Z VAT registration number: GB Copyright 2016 PatientView Ltd. All rights reserved. This booklet is the property of PatientView, and no part may be reproduced without permission, or passed on to any third party without the permission of PatientView.
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EUROPE EDITION)
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (EUROPE EDITION) Feedback from 797 patient groups in Europe PUBLISHED APRIL 2016 The perception [of pharma] has changed in the last years,
More informationTHE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 118 PATIENT GROUPS with an interest in RESPIRATORY CONDTIONS
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 118 PATIENT GROUPS with an interest in RESPIRATORY CONDTIONS PUBLISHED OCTOBER 2016 [Question to respondents: Which companies have the best record
More informationTHE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (NORDIC EDITION)
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (NORDIC EDITION) Feedback from 147 Nordic patient groups PUBLISHED JUNE 2016 Syöpälääkkeiden kehitys on ollut hyvä, ja yhä useammat paranevat.
More informationTHE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (SPANISH EDITION)
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (SPANISH EDITION) Feedback from 108 Spanish patient groups PUBLISHED MAY 2016 Nuevos tratamientos con precios que impidan el acceso para
More informationTHE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (GERMAN EDITION)
THE CORPORATE REPUTATION OF PHARMA THE PATIENT PERSPECTIVE IN 2015 (GERMAN EDITION) Feedback from 60 German patient groups PUBLISHED JUNE 2016 Die neuen, extrem hohen Hepatitis-C- Medikamenten-Preise haben
More informationCorporate Reputation of Pharma in 2017 the Patient Perspective
PRESS RELEASE: 'Corporate Reputation of Pharma in - the Global Patient Perspective' Corporate Reputation of Pharma in the Patient Perspective EMBARGOED PRESS RELEASE: 6AM GMT, THURSDAY, APRIL 5TH 2018
More informationFrance Pharma RepTrak 2017
France Pharma RepTrak 2017 The World s Most Reputable Pharmaceutical Companies in France Olivier Forlini, Director Reputation Institute France June 2017 1 Why Measure Reputation? The success of your company
More informationDatamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar
Datamonitor Healthcare 2017 Datamonitor Healthcare Content Calendar 2017 Content Calendar Published February 2017 Datamonitor Healthcare provides up-to-date insights and analysis that you can trust. Disease
More informationStrategic vision of Pharma Market
Strategic vision of Pharma Market Evolution 2012-2016 ACIP Presentation, Paris January 30, 2013 Introduction This presentation draws strategic orientations for pharma companies considering the expected
More informationGLOBAL MARKETS FOR DRUG REPURPOSING
GLOBAL MARKETS FOR DRUG REPURPOSING PHM175A January 2016 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-202-8 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationIMPROVING TALENT ACQUISITON OUTCOMES
IMPROVING TALENT ACQUISITON OUTCOMES Harry Griendling Founder & CEO March, 2017 2017 DoubleStar, Inc. Proprietary work product. Reproduction or external distribution without prior permission is strictly
More informationMarch 17, 2018 Ranking the Experience of European Physicians Interactions With Pharma. by Tim van Tongeren with Dennis van Rooij and Carlos Capella
March 17, 2018 Ranking the Experience of European Physicians Interactions With Pharma by Tim van Tongeren with Dennis van Rooij and Carlos Capella Executive Summary Each year, the pharmaceutical industry
More informationPharmaceutical Companies and Social Media: Developing New Strategies
Pharmaceutical Companies and Social Media: Developing New Strategies Jena Cutie jena@saaraams.com Karthika Karindalam karthika@saaraams.com 1 2 3 Executive Summary Best Practices and Strategies Pharma
More informationEvaluate Data Kit Pharma, Biotech and Medtech, May 2018
Evaluate Data Kit Pharma, Biotech and Medtech, May 2018 Contents Introduction 2 Sourcing Instructions / About Evaluate 3 Section 1 Pharma Industry Overview Top 15 Rx and OTC Sales 4 WW Rx and OTC Sales
More informationAsia Pac Compliance Code and APEC Principles and Nanjing Declaration Updates - Healthier China Through Innovation
Asia Pac Compliance Code and APEC Principles and Nanjing Declaration Updates - Healthier China Through Innovation Henry Li, General Counsel, RDPAC Beijing, China About RDPAC: R&D based Pharmaceutical Association
More informationGLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS
GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BIO021E May 2016 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-288-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationTheme Sub-theme Quote / issue. Inconsistency and
Theme Sub-theme Quote / issue Inconsistency and ambiguity Problematic and contradictory use of the term "all". Abbvie's webpage describing their transparency policy says "AbbVie will submit a manuscript
More informationGLOBAL MARKETS FOR BIOENGINEERED PROTEIN DRUGS
GLOBAL MARKETS FOR BIOENGINEERED PROTEIN DRUGS BIO009G January 2017 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-417-9 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationGlobal Oncology Biosimilars Market
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oncology Biosimilars Market 2016-2020 Global Oncology Biosimilars Market 2016-2020 Publication ID: TNV0216071
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationImportant notice. 139 th Ordinary general meeting of shareholders. Christophe Weber President & Chief Executive Officer
139 th Ordinary general meeting of shareholders Christophe Weber President & Chief Executive Officer June 26, 2015 Important notice Forward-Looking Statements This presentation contains forward-looking
More informationCode of Conduct Interfarma Review 2012
Code of Conduct Interfarma Review 2012 Segundo Congreso Latinoamericano de Compliance de la Industria Farmacéutica e Insumos para la Salud, y el Foro de Buenas Prácticas Interfarma has a cooperation agreement
More informationBIOPHARMACEUTICALS A GLOBAL MARKET OVERVIEW
BIOPHARMACEUTICALS A GLOBAL MARKET OVERVIEW The study reviews, analyzes and projects the global market for Biopharmaceuticals for the period 2006 2015 PUBLISHED: APRIL 2010 Report Code: BT001 Pages: 240
More informationThema: Maatschappelijke verantwoordelijkheid van de farmaceutische industrie: beschikbaarheid en betaalbaarheid van de toegang tot zorg
Thema: Maatschappelijke verantwoordelijkheid van de farmaceutische industrie: beschikbaarheid en betaalbaarheid van de toegang tot zorg Farma uitgedaagd. Kunnen wij spreken van fair medicine? Carin Uyl-de
More informationTable of contents. Executive Summary. Chapter 1 Introduction. Chapter 2 Trends in monoclonal antibody dealmaking
Table of contents Executive Summary Chapter 1 Introduction Chapter 2 Trends in monoclonal antibody dealmaking 2.1. Introduction 2.2. Monoclonal antibody partnering over the years 2.3. Bigpharma monoclonal
More informationLSE Health Market Access Academy April 2018, London September 2018, London
LSE Health Market Access Academy 9 13 April 2018, London 10 14 September 2018, London In cooperation with the Boston Consulting Group Market Access Roundtable LSE Health Market Access Academy 2 The London
More informationUSP Packing General Chapters <661.1>, <381>, <665>: An Industry Perspective on Elemental Impurities Compliance for Container/Closure
USP Packing General Chapters , , : An Industry Perspective on Elemental Impurities Compliance for Container/Closure Tim Shelbourn Co-chair, IQ Consortium ICH Q3D Compliance Working Group
More informationThe Changing Pharma Commercial Model in 2010 and Beyond Delivering the Customer Experiences Physicians Want Author: John Mack
www.pharmamarketingnews.com May 2010 Vol. 9, No. 5 Published by VirSci Corp. www.virsci.com Webinar Highlight/Service Review The Changing Pharma Commercial Model in 2010 and Beyond Delivering the Customer
More informationBest-in-Class Pharma Strategy. Crafting. Data. Concepts. Methods. Tools. Smart Pharma Consulting Expertise. March Smart Pharma Consulting
Best-in-Class Pharma Strategy Data Crafting Concepts Methods Tools Smart Pharma Consulting Expertise March 208 Smart Pharma Consulting Table of Contents Smart Pharma Expertise p.3 3. Strategy Crafting
More informationNew paths to value creation in pharma
New paths to value creation in pharma In a changing industry, survival increasingly depends on leading in categories and distinctive business capabilities. By Nils Behnke, Michael Retterath, Todd Sangster
More informationBIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
: TECHNOLOGIES AND GLOBAL MARKETS BIO061C April 2014 Jackson Highsmith Project Analyst ISBN: 1-56965-801-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within
More informationPHARMACEUTICAL HUB SWITZERLAND BASEL REGION
PHARMACEUTICAL HUB SWITZERLAND BASEL REGION TABLE OF CONTENTS Preface 4 Pharmaceutical Industry in Switzerland 6 Swiss Pharmaceutical Cluster 8 Basel Region 10 Innovation Capacity 18 Inward Investment
More informationTHE STATE OF CUSTOMER EXPERIENCE IN EUROPEAN PHARMA, 2017: PHYSICIAN INTERACTIONS
September 12, 2017 THE STATE OF CUSTOMER EXPERIENCE IN EUROPEAN PHARMA, 2017: PHYSICIAN INTERACTIONS Novo Nordisk, Bristol-Myers Squibb, And Roche Are Top Performers by Tim van Tongeren with Dennis van
More informationPASS-PAES-HTA studies
PASS-PAES-HTA studies A view from academia Nicholas Moore University of Bordeaux Disclosure 2 Conflict of interest statement I & my department have worked or are working with, or have received various
More informationEquity Strategy Across the Atlantic: Comparing and Contrasting Equity Practices at Big Pharma Companies in Europe and the United States
Equity Strategy Across the Atlantic: Comparing and Contrasting Equity Practices at Big Pharma Companies in Europe and the United States By: Robert Miller, Partner Team: Published: October 2014 Introduction
More informationby Dennis van Rooij and Tim van Tongeren
July 10, 2015 DISCIPLINE DRIVES DIGITAL EXCELLENCE IN PHARMA Digital Teams Are Change Agents As Much As They Are Capability Engineers by Dennis van Rooij and Tim van Tongeren EXECUTIVE SUMMARY A new wave
More informationMultiple Sclerosis Treatment Market Research Report - Global Forecast till 2023
Report Information More information from: https://www.marketresearchfuture.com/reports/940 Multiple Sclerosis Treatment Market Research Report - Global Forecast till 2023 Report / Search Code: MRFR/HC/0434-HCRR
More informationPharmaceuticals and Product Stewardship. Sierra Fletcher Product Stewardship Institute April 29, 2011
Pharmaceuticals and Product Stewardship Sierra Fletcher Product Stewardship Institute Who is the Product Stewardship Institute? Non profit founded in 2000 Membership 47 States 200+ Local governments 70+
More information2016 Clinical Trials Roundup: The Next Generation
2016 Clinical Roundup: The Next Generation Doro Shin Thought Leadership Manager Introduction Welcome to this year s Clinical Roundup where we ll reflect on research initiated in 2016, dissecting the data
More informationPublic private partnerships to encourage patient access
Public private partnerships to encourage patient access 5 th SFE SFUS Conference Challenges for efficient health care in Central and Eastern Europe Belgrade, 10 th October 2015 How does IMI work? The Innovative
More informationRepresenting Healthcare Distribution in Canada
Representing Healthcare Distribution in Canada OUR VISION Ensuring safe, secure, and timely access to life-saving medicines and quality healthcare products for every Canadian. OUR COMMITMENT IMPLEMENTING
More informationDisclosures and Acknowledgments
214 Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis Dallas, Texas DX1 Disability Progression in Multiple Sclerosis
More informationIndustry Biomanufacturing Capacity Overview Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. DCAT March 14 17, 2016
Global Biomanufacturing Trends, Capacity and Technology Drivers Industry Biomanufacturing Capacity Overview Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. DCAT March 14 17, 2016
More informationA European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director
A European Public-Private Partnership! in Healthcare! Michel Goldman, MD,PhD Executive Director ITMAT 2010, 27 October 2010 EFPIA Member Companies Participating companies (September 2010):! Innovative
More informationGlobal Demand and Utilization of Mammalian Cell Culture Manufacturing Capacity
Global Demand and Utilization of Mammalian Cell Culture Manufacturing Capacity Howard L. Levine, Ph.D. Eighth Annual BioProcess International Europe 2012 Apr 18-19 Prague, Czech Republic BioProcess Technology
More informationThe Patient-Reported Outcome (PRO) Consortium:
The Patient-Reported Outcome (PRO) Consortium: A Collaborative Approach to PRO Instrument Development and Qualification Stephen Joel Coons, PhD Executive Director The views and opinions expressed in the
More informationGeneric Series: Optimizing Brand Lifecycle Management
A Datamonitor report Generic Series: Optimizing Brand Lifecycle Management Winning Strategies to Maximize Revenue in the Face of Growing Generic Competition Published: Jun-08 Product Code: Providing you
More informationSponsorship & Branding opportunities
Learn. Connect. Optimize. Tuesday, June 26, 2018 Hyatt regency Hotel, New Brunswick, New Jersey education Forums networking keynote speaker Sponsorship & Branding opportunities Limited Sponsorships available!
More informationHelping Pharmas Manage Compliance Risks for Speaker Programs
COGNIZANT 20-20 Helping Pharmas Manage Compliance Risks for Speaker Programs By taking a rigorous and thoughtful approach that pivots around key performance indicators, pharmaceuticals companies can proactively
More informationWhich companies are attending this year?
5 th June 2017 Which companies are attending this year? Note: These are the companies who have given us permission to publish the company name and job title of those who are attending the conference this
More informationProduct Overview: Global Life Sciences Survey. One Firm. Complete Solutions.
Product Overview: Global Life Sciences Survey One Firm. Complete Solutions. Unmatched Life Sciences Expertise 59 Reporting Countries 812 Participating Organizations 1,900 Unique Jobs Surveyed 390 Thousand
More informationClinical trial landscape trial completions
Clinical trial landscape 2015 trial completions A2 March 2016 Informa UK Ltd 2016 (Unauthorized photocopying prohibited.) Christine Blazynski, PhD Head of Innovation Pharma Intelligence Informa 2015 Trial
More informationThe Best of. SmartPharma. Concepts. Methods. Tools. Smart Pharma. Consulting. Strategy. Marketing & Sales. Management.
The Best of Smart Pharma Concepts Methods Tools 208 SmartPharma Consulting Strategy Pharma Market Perspectives 2023 Pharma Strategy Crafting Marketing & Sales Pharma Market Research Pharma Field Force
More informationClinical Trials in Ukraine Orange Paper Annual Summary
Orange Paper 2016 Annual Summary CRO Synergy Group Ukraine 48/50, Volynska str., Kyiv, 03151, Ukraine www.synrg-pharm.com Contents Executive Summary... 3 Clinical Trials by Type... 4 Figure 1. Clinical
More informationPersonalized healthcare Getting from promise to reality
Personalized healthcare Getting from promise to reality Severin Schwan, CEO Roche Group Swiss-American Chamber of Commerce, 26 August 2009 1 Roche The challenge Personalised healhcare Implementation at
More informationSafeSciMET. European Modular Education and Training Programme in Safety Sciences for Medicines
SafeSciMET European Modular Education and Training Programme in Safety Sciences for Medicines What patients need What Europe needs Rapid exploitation of insights in disease mechanisms for introduction
More informationThe Innovative Medicines Initiative
The Innovative Medicines Initiative Innovative funding for biotechs & SMEs in Europe Pierre Meulien, IMI Executive Director BIO-Europe Conference, Copenhagen 06.11.2018 IMI Europe s partnership for health
More informationNEXT Annual Report 2017
NEXT Annual Report 2017 June 2018 Final version NEXT Annual Report 2017 Executive Summary The number of early clinical trials carried out in the centers exceeded the number anticipated in the original
More informationPharma RepTrak The World s Most Reputable Pharmaceu<cal Companies. May 2016
Pharma RepTrak 2016 The World s Most Reputable Pharmaceu
More informationCurrent Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V
Current Status of Pharmaceutical Patenting at United States Patent Office Rau. B. S Appaji P. V Abstract: Indian pharmaceutical industry has proved manufacture of global quality pharmaceutical products
More information2017 Clinical Trials Roundup: The Evolution Continues
2017 Clinical Roundup: The Evolution Continues Doro Shin Content Marketing Director Introduction The landscape of clinical trials continues to evolve over time as scientific breakthroughs and technological
More informationCoordination and Support Action: Enabling platform on medicines adaptive pathways to patients
Coordination and Support Action: Enabling platform on medicines adaptive pathways to patients Solange Rohou (AZ) & Luk Maes (BMS) 17.12.2014 IMI webinar Content Background information CSA project proposal
More informationGlobal and China Biopharmaceutical Industry Report, 2010
Global and China Biopharmaceutical Industry Report, 2010 In recent years, biopharmaceutical industry has been the fastest growing sector in the global pharmaceutical industry. From 1998 to 2009, the compound
More informationCDISC ST R MEMBERSHIP April 2018
Amgen Boehringer Ingelheim Pharmaceuticals Bristol Myers Squibb Certara CompleWare Corporation Duke Clinical Research Institute Eli Lilly and Company GlaxoSmithKline IQVIA Johnson & Johnson Merck & Co.,
More informationBiomanufacturing Capacity for Biosimilars: Is there enough?
Biomanufacturing Capacity for Biosimilars: Is there enough? Cambridge Healthtech Institute s Third Annual BIOAnalytical Summit 2012 Mar 19-22 Baltimore, MD BioProcess Technology Consultants www.bptc.com
More informationPharmaceutical lobbying
FREE ARTICLE Pharmaceutical lobbying Author: Magdalena Nizińska July 2012 A successful market entry of a new medicine requires on one hand obeying the registration procedures, and on the other plenty of
More informationWelcome to. April 4-5, DoubleTree by Hilton Hotel Silver Spring, MD USA
Welcome to April 4-5, 2016 DoubleTree by Hilton Hotel Silver Spring, MD USA What is CASSS? Practical Applications of Mass Spectrometry EUROPE JAPAN NORTH AMERICA SOUTH AMERICA CASSS is the leading non-profit
More informationTHE STATE OF DIGITAL EXCELLENCE IN THE PHARMACEUTICAL INDUSTRY, 2015: CAPABILITIES
April 2, 2015 THE STATE OF DIGITAL EXCELLENCE IN THE PHARMACEUTICAL INDUSTRY, 2015: CAPABILITIES Firms Require a More Disciplined Approach to Improving Digital Maturity by Tim van Tongeren and Dennis van
More informationBREAKTHROUGH INNOVATION: LESSONS FOR PHARMA R&D
BREAKTHROUGH INNOVATION: LESSONS FOR PHARMA R&D Novasecta: Specialist Pharmaceutical Management Consulting The realities of unrelenting price pressure and patent expiries put a special pressure on pharmaceutical
More informationMEDIUS PARTNERING. July Global specialist provider of Business Development services to the Pharmaceutical and Healthcare Sectors
MEDIUS PARTNERING July 2017 Global specialist provider of Business Development services to the Pharmaceutical and Healthcare Sectors Medius Associates Healthcare Business Development consultancy founded
More informationThe Innovative Medicines Initiative: Building new models of collaborative research across Europe
The Innovative Medicines Initiative: Building new models of collaborative research across Europe Elisabetta Vaudano IMI, Belgium www.imi.europa.eu What is IMI? An European Public-Private Partnership Focused
More informationTHE TOP 5 TRENDS IN HCP S DIGITAL PREFERENCE. PHARMAFUTURE. All rights reserved.
THE TOP 5 TRENDS IN HCP S DIGITAL PREFERENCE DISCLAIMER All findings, inferences, and data shared in this report are solely the views of the respondents and may, or may not represent the views of any
More informationFebruary September 11, See, for example, Guidance for Industry on Biosimilars: Q & As Regarding Implementation of the BPCI Act of 2009:
February 2014 Biosimilars: Strategic considerations for interchangeability The future timing, magnitude, and impact of the anticipated biosimilar wave continue to be in flux. Major biopharmaceutical manufacturers
More informationAn Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America
An Industry Perspective: Reducing the Complexity and Impact of Regulatory Changes in Latin America SPEAKERS: Janett Mugaburu-Richards, M.S. Pfizer Inc. Kavita Ramalingam Iyer, Ph.D Merck & Co., Inc. Contents
More informationThe US VBA Tracker Value & Outcomes Based, Innovative Contracting
The US VBA Tracker Value & Outcomes Based, Innovative Contracting January 2018 Copyright, reproduction and data re-use No part of the US VBA Tracker may be reproduced for commercial purpose without the
More informationFull-Disclosure Form
Neuroscience Education Institute Full-Disclosure Form 1930 Palomar Point Way, Ste. 101 Carlsbad, CA 92008 Tel 760-931-8857 Fax 760-931-8713 NEI requires all planners, teachers/speakers, and authors/content
More informationPatients are Counting on Us: It s Time to Act
Patients are Counting on Us: It s Time to Act Brian Johnson Chairman Rx-360 Senior Director Supply Chain Security Pfizer, Inc. 24 th Global GS1 Healthcare Conference October 2, 2013 THE WALL STREET JOURNAL
More informationClinical Trials Insight. World Pharmaceutical Frontiers
ABOUT CLINICAL TRIALS INSIGHT The cost of bringing a new drug to market is staggering. Major pharmaceutical companies now invest between $4 billion and $12 billion in developing each new product. Containing
More informationAnalysis of Lebanon s Pharmaceutical Market
November 2013 Analysis of Lebanon s Pharmaceutical Market (2009 2013) Table of Contents: World Pharmaceutical Market:... 2 Lebanon s Pharmaceutical Market:... 5 Pharmaceutical Imports and Exports:... 7
More informationOnline Disclosure Form Submission
Online Disclosure Form Submission Full-Disclosure Form NEI requires all planners, teachers/speakers, and authors/content developers involved with CME content to disclose all financial relationships with
More informationThe Drug Industry: Pharmaceuticals and Biopharmaceuticals
The Drug Industry: Pharmaceuticals and Biopharmaceuticals Presenter Prof. Geoffrey Poitras Simon Fraser University Vancouver, BC Thursday, Jan. 15, 2015 Disclosure Prof. Poitras is a professor of Finance
More informationWill payer leverage and post-election optimism shift dealmaking into a higher gear?
EY M&A Outlook and Firepower Report 2017 Will payer leverage and post-election optimism shift dealmaking into a higher gear? Payer pressure is growing across a wide spectrum of the health care sector.
More informationInnovative Science Affordable Medicine
Innovative Science Affordable Medicine H1 FY13 Results Presentation : Oct 31, 2012 www.biocon.com Overall Financial Performance H1 FY13 H1 FY12 % Growth Revenue 1,235 1,001 23% EBITDA 305 281 8% 25% 28%
More informationThe SURVIMUS study. A large multicenter study on long-term mortality of multiple sclerosis patients in France
The SURVIMUS study A large multicenter study on long-term mortality of multiple sclerosis patients in France E. Leray, INSERM CIC-P 0203, Epidemiology Department EHESP School of Public Health, Rennes,
More informationParameters of Development - Drug Delivery Enabled/Enhanced Products (DDEP ) A Review (Chapter 7)
CHAPTER 7 FDA DRUG APPROVALS, 2000-2010 Introduction This chapter reviews drug delivery enabled/enhanced product approvals by the FDA over the period 2000-2010. This is a simple analysis that provides
More informationDir Analytical Dev. Sr Stability & Regulatory Scientist. Quality Control Sr Mgr. Principal Scientist
TITLE COMPANY Dir Analytical Dev Patheon Assoc Dir Quality Control Boehringer Ingelheim Sr Stability & Regulatory Scientist GlaxoSmithKline Quality Control Sr Mgr Sr Analytical Chemist Mallinckrodt Technical
More informationMoving from volume to value in the generic business model
Moving from volume to value in the generic business model CPhI Pre-connect conference Frankfurt 23rd October 2017 Copyright 2016 QuintilesIMS. All rights reserved. Key drivers to 2021 Global growth moderating
More informationA2 Micro: Business Objec2ves
A2 Micro: Business Objec2ves A short revision webinar covering profit maximisa5on, changes in costs and revenues and pricing with different business objec5ves Revising A2 Economics (Micro) Build lots of
More informationThe Drug Industry: Pharmaceuticals and Biopharmaceuticals
The Drug Industry: Pharmaceuticals and Biopharmaceuticals Presenter Prof. Geoffrey Poitras Simon Fraser University Vancouver, BC Thursday, March 27, 2014 Disclosure Prof. Poitras is a professor of Finance
More informationPharmaceutical and Biotechnology Construction Sector Report - UK
Pharmaceutical and Biotechnology Construction Sector Report - UK 2018-2022 Published: 26/09/2018 / Number of Pages: 99 / Price: 895.00 Introduction and Overview The 4th edition of the 'Pharmaceutical &
More informationAn Open Letter to the Authors of Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis (Khan et al, 2010, Annals of Neurology)
An Open Letter to the Authors of Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis (Khan et al, 2010, Annals of Neurology) Ashton Embry, Direct-MS Background: A week ago a Point of View
More informationTHE DIGITAL. Top trends SAVVY HCP
Top trends THE DIGITAL SAVVY HCP 2017 02 / THE DIGITAL SAVVY HCP 2017 THE DIGITAL SAVVY HCP 2017 / 03 Executive Summary In our previous report THE DIGITAL SAVVY HCP 2015, we had noted a Respondent Demographics
More informationWelcome to. January 26, The Mayflower Hotel Washington, DC USA
Welcome to January 26, 2015 The Mayflower Hotel Washington, DC USA Mission Statement Provide a venue for biotechnology/biological product discussion that focuses on relevant CMC issues throughout the lifecycle
More informationUNLEASHING MEDICAL AFFAIRS
UNLEASHING MEDICAL AFFAIRS DEC 2017 UNLEASHING MEDICAL AFFAIRS Sweeping changes across the pharmaceutical industry have heightened the expectations for Medical Affairs and have created an unprecedented
More informationInnovation for Pharma to engage with the mobile user.
www.healthnetworkcommunications.com/mobile Innovation for Pharma to engage with the mobile user 24-27 April 2012 Sheraton Hotel, Amsterdam, The Netherlands created by sponsor endorsed by Smart phones and
More informationProgram Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven
Program Coordinator Medication Assistance Program Smilow Cancer Hospital at Yale New Haven Yale MAP Program Consists of 5 FTE s Has been established for five years Was originally mirrored from the Ohio
More informationBusiness Development & Licensing Journal
www.plgeurope.com Business Development & Licensing Journal For the Pharmaceutical Licensing Groups Strategic options for getting the most out of late-stage licensing deals Trends in the therapeutic area
More informationCMC Strategy Forum Prague Enda Moran EBE Satellite Session, 06 May 2013
CMC Strategy Forum Prague 2013 Enda Moran EBE Satellite Session, 06 May 2013 European Biopharmaceutical Enterprises EBE s VISION: fostering innovation, and promote favorable business and regulatory conditions
More informationWorkshop on Cytokine Release: State-of-the-Science, Current Challenges and Future Directions
Workshop on Cytokine Release: State-of-the-Science, Current Challenges and Future Directions Sponsored by the HESI Immunotoxicology Technical Committee Silver Spring, MD 22 October 2013 Objectives of the
More informationSUPERGENERICS BIOSIMILARS Biosimilars (Continued) TABLE 3 BIOLOGICS FACING THE LAUNCH OF BIOSIMILARS,
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 2 MARKET ANALYSES AND FORECASTS... 2 METHODOLOGY... 2 INTENDED AUDIENCE... 3 INFORMATION
More information